Human Gene MYC (ENST00000621592.8_13) from GENCODE V47lift37
  Description: MYC proto-oncogene, bHLH transcription factor, transcript variant 1 (from RefSeq NM_002467.6)
Gencode Transcript: ENST00000621592.8_13
Gencode Gene: ENSG00000136997.22_22
Transcript (Including UTRs)
   Position: hg19 chr8:128,748,477-128,755,197 Size: 6,721 Total Exon Count: 3 Strand: +
Coding Region
   Position: hg19 chr8:128,748,840-128,753,204 Size: 4,365 Coding Exon Count: 3 

Page IndexSequence and LinksUniProtKB CommentsPrimersMalaCardsCTD
Gene AllelesMicroarray ExpressionRNA StructureProtein StructureOther SpeciesGO Annotations
mRNA DescriptionsPathwaysOther NamesModel InformationMethods
Data last updated at UCSC: 2024-08-22 23:36:26

-  Sequence and Links to Tools and Databases
 
Genomic Sequence (chr8:128,748,477-128,755,197)mRNA (may differ from genome)Protein (454 aa)
Gene SorterGenome BrowserOther Species FASTAVisiGeneGene interactionsTable Schema
AlphaFoldBioGPSEnsemblEntrez GeneExonPrimerGeneCards
HGNCMalacardsMGIOMIMPubMedReactome
UniProtKBWikipediaBioGrid CRISPR DB

-  Comments and Description Text from UniProtKB
  ID: MYC_HUMAN
DESCRIPTION: RecName: Full=Myc proto-oncogene protein; AltName: Full=Class E basic helix-loop-helix protein 39; Short=bHLHe39; AltName: Full=Proto-oncogene c-Myc; AltName: Full=Transcription factor p64;
FUNCTION: Participates in the regulation of gene transcription. Binds DNA in a non-specific manner, yet also specifically recognizes the core sequence 5'-CAC[GA]TG-3'. Seems to activate the transcription of growth-related genes.
SUBUNIT: Efficient DNA binding requires dimerization with another bHLH protein. Binds DNA as a heterodimer with MAX. Interacts with TAF1C and SPAG9. Interacts with PARP10. Interacts with KDM5A and KDM5B. Interacts (when phosphorylated at Thr-58 and Ser-62) with FBXW7. Interacts with PIM2 (By similarity). Interacts with NO66.
INTERACTION: P03070:- (xeno); NbExp=2; IntAct=EBI-447544, EBI-617698; Q15059:BRD3; NbExp=3; IntAct=EBI-447544, EBI-1383460; P11802:CDK4; NbExp=2; IntAct=EBI-447544, EBI-295644; Q86XR8:CEP57; NbExp=3; IntAct=EBI-447544, EBI-308614; Q14839:CHD4; NbExp=2; IntAct=EBI-447544, EBI-372916; O15111:CHUK; NbExp=3; IntAct=EBI-447544, EBI-81249; Q15029:EFTUD2; NbExp=5; IntAct=EBI-447544, EBI-357897; Q969H0:FBXW7; NbExp=2; IntAct=EBI-447544, EBI-359574; Q8N3Y1:FBXW8; NbExp=3; IntAct=EBI-447544, EBI-914770; Q92769:HDAC2; NbExp=2; IntAct=EBI-447544, EBI-301821; Q8TCG1:KIAA1524; NbExp=2; IntAct=EBI-447544, EBI-1379376; Q8N163:KIAA1967; NbExp=8; IntAct=EBI-447544, EBI-355410; P61244:MAX; NbExp=21; IntAct=EBI-447544, EBI-751711; P52164:Max (xeno); NbExp=4; IntAct=EBI-447544, EBI-1184963; P33993:MCM7; NbExp=6; IntAct=EBI-447544, EBI-355924; O75928:PIAS2; NbExp=4; IntAct=EBI-447544, EBI-348555; Q96EB6:SIRT1; NbExp=4; IntAct=EBI-447544, EBI-1802965; Q13309:SKP2; NbExp=2; IntAct=EBI-447544, EBI-456291; Q8TAD8:SNIP1; NbExp=9; IntAct=EBI-447544, EBI-749336; P08047:SP1; NbExp=4; IntAct=EBI-447544, EBI-298336; P11387:TOP1; NbExp=2; IntAct=EBI-447544, EBI-876302; Q9Y4A5:TRRAP; NbExp=4; IntAct=EBI-447544, EBI-399128; P17480:UBTF; NbExp=2; IntAct=EBI-447544, EBI-396235; Q13105:ZBTB17; NbExp=2; IntAct=EBI-447544, EBI-372156;
SUBCELLULAR LOCATION: Nucleus, nucleoplasm. Nucleus, nucleolus.
PTM: Phosphorylated by PRKDC. Phosphorylation at Thr-58 and Ser-62 by GSK3 is required for ubiquitination and degradation by the proteasome. Phosphorylation at Ser-329 by PIM2 leads to the stabilization of MYC (By similarity). Phosphorylation at Ser-62 by CDK2 prevents Ras-induced senescence.
PTM: Ubiquitinated by the SCF(FBXW7) complex when phosphorylated at Thr-58 and Ser-62, leading to its degradation by the proteasome. In the nucleoplasm, ubiquitination is counteracted by USP28, which interacts with isoform 1 of FBXW7 (FBW7alpha), leading to its deubiquitination and preventing degradation. In the nucleolus, however, ubiquitination is not counteracted by USP28, due to the lack of interaction between isoform 4 of FBXW7 (FBW7gamma) and USP28, explaining the selective MYC degradation in the nucleolus. Also polyubiquitinated by the DCX(TRUSS) complex.
DISEASE: Note=Overexpression of MYC is implicated in the etiology of a variety of hematopoietic tumors.
DISEASE: Note=A chromosomal aberration involving MYC may be a cause of a form of B-cell chronic lymphocytic leukemia. Translocation t(8;12)(q24;q22) with BTG1.
DISEASE: Defects in MYC are a cause of Burkitt lymphoma (BL) [MIM:113970]. A form of undifferentiated malignant lymphoma commonly manifested as a large osteolytic lesion in the jaw or as an abdominal mass. Note=Chromosomal aberrations involving MYC are usually found in Burkitt lymphoma. Translocations t(8;14), t(8;22) or t(2;8) which juxtapose MYC to one of the heavy or light chain immunoglobulin gene loci.
BIOTECHNOLOGY: POU5F1/OCT4, SOX2, MYC/c-Myc and KLF4 are the four Yamanaka factors. When combined, these factors are sufficient to reprogram differentiated cells to an embryonic-like state designated iPS (induced pluripotent stem) cells. iPS cells exhibit the morphology and growth properties of ES cells and express ES cell marker genes.
SIMILARITY: Contains 1 bHLH (basic helix-loop-helix) domain.
WEB RESOURCE: Name=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/MYCID27.html";
WEB RESOURCE: Name=NIEHS-SNPs; URL="http://egp.gs.washington.edu/data/myc/";
WEB RESOURCE: Name=Wikipedia; Note=Myc entry; URL="http://en.wikipedia.org/wiki/Myc";

-  Primer design for this transcript
 

Primer3Plus can design qPCR Primers that straddle exon-exon-junctions, which amplify only cDNA, not genomic DNA.
Click here to load the transcript sequence and exon structure into Primer3Plus

Exonprimer can design one pair of Sanger sequencing primers around every exon, located in non-genic sequence.
Click here to open Exonprimer with this transcript

To design primers for a non-coding sequence, zoom to a region of interest and select from the drop-down menu: View > In External Tools > Primer3


-  MalaCards Disease Associations
  MalaCards Gene Search: MYC
Diseases sorted by gene-association score: burkitt lymphoma* (1422), precursor t-cell acute lymphoblastic leukemia* (175), lymphoma (32), childhood medulloblastoma (31), diffuse large b-cell lymphoma (27), mature b-cell neoplasm (19), diffuse large b-cell lymphoma of the central nervous system (19), plasmacytoma (16), b-cell lymphomas (15), large cell medulloblastoma (15), lymphoma, large-cell, immunoblastic (15), gallbladder signet ring cell adenocarcinoma (14), osteosarcoma, somatic (14), primary effusion lymphoma (14), b cell prolymphocytic leukemia (13), lung cancer (12), multiple myeloma (12), prolymphocytic leukemia (12), ocular cancer (12), follicular lymphoma (11), nut midline carcinoma (11), hepatocellular carcinoma (11), richter's syndrome (10), cervical cancer, somatic (10), hepatic angiomyolipoma (10), ovarian angiosarcoma (9), ovary sarcoma (9), htlv-1 associated myelopathy/tropical spastic paraparesis (9), askin's tumor (9), breast cancer (9), colorectal cancer (9), uterine corpus cancer (9), familial adenomatous polyposis (8), medulloblastoma (8), chronic venous leg ulcers (8), anal carcinoma in situ (8), vulva basal cell carcinoma (8), angiosarcoma (8), hemimegalencephaly (8), gastric adenocarcinoma (8), fallopian tube carcinoma (7), megaesophagus (7), lymphoma, non-hodgkin (7), ventricular tachycardia, catecholaminergic polymorphic, 3 (7), bile duct carcinoma (7), plasma cell neoplasm (7), autosomal dominant polycystic kidney disease (7), t-cell prolymphocytic leukemia (7), holoprosencephaly 4 (7), lung giant cell carcinoma (7), mantle cell lymphoma (7), juvenile nasopharyngeal angiofibroma (6), medullomyoblastoma (6), myasthenic syndrome, congenital, 14, with tubular aggregates (6), infratentorial cancer (6), myeloid leukemia (6), acquired immunodeficiency syndrome (6), lymphatic system cancer (6), pediatric systemic lupus erythematosus (6), leukodystrophy, hypomyelinating, 4 (6), breast adenoma (6), cerebral primitive neuroectodermal tumor (6), lymphoblastic lymphoma (6), endometrial cancer (6), ovarian lymphoma (6), adenomatous polyposis coli (5), malignant histiocytosis (5), lymphoblastic leukemia (5), marcus gunn phenomenon (5), venous hemangioma (5), malignant biphasic mesothelioma (5), glioblastoma multiforme (5), kaposi sarcoma (5), germ cell and embryonal cancer (5), malignant fibrous histiocytoma of bone (5), sensory system cancer (5), retinal cancer (5), fibrosarcoma of bone (5), adult lymphoma (5), autonomic nervous system neoplasm (4), peripheral nervous system neoplasm (4), cornelia de lange syndrome (4), esophagus adenocarcinoma (4), nervous system cancer (4), neonatal leukemia (4), lymphangiosarcoma (4), bone ewing's sarcoma (4), prostate cancer (4), chronic lymphocytic leukemia (3), ovarian cancer, somatic (3), esophageal cancer (3), urinary bladder cancer (3), oral squamous cell carcinoma (3), leukemia, acute promyelocytic, somatic (2), leukemia, chronic myeloid, somatic (2), stomach cancer (2), breast adenocarcinoma (2), gastrointestinal system cancer (2), squamous cell carcinoma, head and neck (1), adamantinoma of long bones (1), cell type cancer (1), reproductive organ cancer (1), neuroblastoma (1), male reproductive organ cancer (1), female reproductive organ cancer (1), gastric cancer, somatic (1), leukemia, acute myeloid (1)
* = Manually curated disease association

-  Comparative Toxicogenomics Database (CTD)
  The following chemicals interact with this gene

+  Common Gene Haplotype Alleles
  Press "+" in the title bar above to open this section.

+  Microarray Expression Data
  Press "+" in the title bar above to open this section.

-  mRNA Secondary Structure of 3' and 5' UTRs
 
RegionFold EnergyBasesEnergy/Base
Display As
5' UTR -157.80363-0.435 Picture PostScript Text
3' UTR -515.001993-0.258 Picture PostScript Text

The RNAfold program from the Vienna RNA Package is used to perform the secondary structure predictions and folding calculations. The estimated folding energy is in kcal/mol. The more negative the energy, the more secondary structure the RNA is likely to have.

-  Protein Domain and Structure Information
  InterPro Domains: Graphical view of domain structure
IPR011598 - HLH_dom
IPR003327 - Myc-LZ
IPR002418 - Tscrpt_reg_Myc
IPR012682 - Tscrpt_reg_Myc_N

Pfam Domains:
PF00010 - Helix-loop-helix DNA-binding domain
PF01056 - Myc amino-terminal region
PF02344 - Myc leucine zipper domain

SCOP Domains:
47459 - HLH, helix-loop-helix DNA-binding domain
57959 - Leucine zipper domain

Protein Data Bank (PDB) 3-D Structure
MuPIT help
1A93 - NMR 1EE4 - X-ray 1MV0 - NMR MuPIT 1NKP - X-ray MuPIT 2A93 - NMR


ModBase Predicted Comparative 3D Structure on P01106
FrontTopSide
The pictures above may be empty if there is no ModBase structure for the protein. The ModBase structure frequently covers just a fragment of the protein. You may be asked to log onto ModBase the first time you click on the pictures. It is simplest after logging in to just click on the picture again to get to the specific info on that model.

-  Orthologous Genes in Other Species
  Orthologies between human, mouse, and rat are computed by taking the best BLASTP hit, and filtering out non-syntenic hits. For more distant species reciprocal-best BLASTP hits are used. Note that the absence of an ortholog in the table below may reflect incomplete annotations in the other species rather than a true absence of the orthologous gene.
MouseRatZebrafishD. melanogasterC. elegansS. cerevisiae
No orthologNo orthologNo orthologNo orthologNo orthologNo ortholog
Gene DetailsGene Details    
Gene SorterGene Sorter    
 RGD    
      
      

-  Gene Ontology (GO) Annotations with Structured Vocabulary
  Molecular Function:
GO:0000978 RNA polymerase II core promoter proximal region sequence-specific DNA binding
GO:0000981 RNA polymerase II transcription factor activity, sequence-specific DNA binding
GO:0001077 transcriptional activator activity, RNA polymerase II core promoter proximal region sequence-specific binding
GO:0003677 DNA binding
GO:0003700 transcription factor activity, sequence-specific DNA binding
GO:0005515 protein binding
GO:0008134 transcription factor binding
GO:0033613 activating transcription factor binding
GO:0044877 macromolecular complex binding
GO:0046983 protein dimerization activity
GO:0070491 repressing transcription factor binding
GO:0070888 E-box binding

Biological Process:
GO:0000082 G1/S transition of mitotic cell cycle
GO:0000122 negative regulation of transcription from RNA polymerase II promoter
GO:0000165 MAPK cascade
GO:0001658 branching involved in ureteric bud morphogenesis
GO:0002053 positive regulation of mesenchymal cell proliferation
GO:0006112 energy reserve metabolic process
GO:0006338 chromatin remodeling
GO:0006351 transcription, DNA-templated
GO:0006355 regulation of transcription, DNA-templated
GO:0006357 regulation of transcription from RNA polymerase II promoter
GO:0006366 transcription from RNA polymerase II promoter
GO:0006879 cellular iron ion homeostasis
GO:0006974 cellular response to DNA damage stimulus
GO:0007050 cell cycle arrest
GO:0007219 Notch signaling pathway
GO:0008284 positive regulation of cell proliferation
GO:0010332 response to gamma radiation
GO:0010468 regulation of gene expression
GO:0010628 positive regulation of gene expression
GO:0015671 oxygen transport
GO:0016579 protein deubiquitination
GO:0019221 cytokine-mediated signaling pathway
GO:0032204 regulation of telomere maintenance
GO:0032873 negative regulation of stress-activated MAPK cascade
GO:0032986 protein-DNA complex disassembly
GO:0034644 cellular response to UV
GO:0035690 cellular response to drug
GO:0042493 response to drug
GO:0043066 negative regulation of apoptotic process
GO:0043280 positive regulation of cysteine-type endopeptidase activity involved in apoptotic process
GO:0044346 fibroblast apoptotic process
GO:0045656 negative regulation of monocyte differentiation
GO:0045893 positive regulation of transcription, DNA-templated
GO:0045944 positive regulation of transcription from RNA polymerase II promoter
GO:0048146 positive regulation of fibroblast proliferation
GO:0048147 negative regulation of fibroblast proliferation
GO:0050679 positive regulation of epithelial cell proliferation
GO:0051276 chromosome organization
GO:0051782 negative regulation of cell division
GO:0051973 positive regulation of telomerase activity
GO:0060070 canonical Wnt signaling pathway
GO:0070371 ERK1 and ERK2 cascade
GO:0070848 response to growth factor
GO:0071456 cellular response to hypoxia
GO:0090096 positive regulation of metanephric cap mesenchymal cell proliferation
GO:1904837 beta-catenin-TCF complex assembly
GO:2000573 positive regulation of DNA biosynthetic process
GO:2001022 positive regulation of response to DNA damage stimulus

Cellular Component:
GO:0000790 nuclear chromatin
GO:0005634 nucleus
GO:0005654 nucleoplasm
GO:0005730 nucleolus
GO:0032991 macromolecular complex


-  Descriptions from all associated GenBank mRNAs
  M13930 - Human c-myc-P64 mRNA, initiating from promoter P0, (HLmyc3.1) partial cds.
M13929 - Human c-myc-P64 mRNA, initiating from promoter P0, (HLmyc2.5) partial cds.
FW411711 - NUCLEIC ACID COMPOUNDS FOR INHIBITING MYC GENE EXPRESSION AND USES THEREOF.
V00568 - Human mRNA encoding the c-myc oncogene.
AK303921 - Homo sapiens cDNA FLJ53953 complete cds, highly similar to Myc proto-oncogene protein (c-Myc)(Transcription factor p64).
AK312883 - Homo sapiens cDNA, FLJ93327, Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian) (MYC), mRNA.
BC000917 - Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian), mRNA (cDNA clone MGC:5184 IMAGE:3048750), complete cds.
K02276 - Human (Daudi) translocated t(8;14) c-myc oncogene mRNA, complete cds.
JD186430 - Sequence 167454 from Patent EP1572962.
BC000141 - Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian), mRNA (cDNA clone MGC:5183 IMAGE:2985844), complete cds.
FW340096 - Screening.
JD423265 - Sequence 404289 from Patent EP1572962.
JD116438 - Sequence 97462 from Patent EP1572962.
LF213368 - JP 2014500723-A/20871: Polycomb-Associated Non-Coding RNAs.
JD290744 - Sequence 271768 from Patent EP1572962.
BC058901 - Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian), mRNA (cDNA clone MGC:64962 IMAGE:6012670), complete cds.
JD479153 - Sequence 460177 from Patent EP1572962.
JD418626 - Sequence 399650 from Patent EP1572962.
KC782559 - Homo sapiens cMyc splice variant mRNA, complete cds, alternatively spliced.
AB528585 - Synthetic construct DNA, clone: pF1KE0200, Homo sapiens MYC gene for v-myc myelocytomatosis viral oncogene homolog, without stop codon, in Flexi system.
HW243463 - JP 2013512690-A/14: RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS.
LF715485 - JP 2016171804-A/14: RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS.
LF205591 - JP 2014500723-A/13094: Polycomb-Associated Non-Coding RNAs.
BD235597 - DNAzyme for treating restenosis.
BD235598 - DNAzyme for treating restenosis.
AB527619 - Synthetic construct DNA, clone: pF1KE0914, Homo sapiens MYC gene for v-myc myelocytomatosis viral oncogene homolog, without stop codon, in Flexi system.
AB528057 - Synthetic construct DNA, clone: pF1KE1082, Homo sapiens MYC gene for Myc proto-oncogene protein, without stop codon, in Flexi system.
DQ894085 - Synthetic construct Homo sapiens clone IMAGE:100008545; FLH167552.01L; RZPDo839C0389D v-myc myelocytomatosis viral oncogene homolog (avian) (MYC) gene, encodes complete protein.
BT019768 - Homo sapiens v-myc myelocytomatosis viral oncogene homolog (avian) mRNA, complete cds.
E01841 - cDNA encoding human C-myc protein.
LF346363 - JP 2014500723-A/153866: Polycomb-Associated Non-Coding RNAs.
LF346365 - JP 2014500723-A/153868: Polycomb-Associated Non-Coding RNAs.
X66258 - H.sapiens c-myc mRNA, partial CDS.
CS544999 - Sequence 108 from Patent WO2006028967.
DL262825 - Regulation of Oncogenes by MicroRNAs.
HW270304 - JP 2012105669-A/100: Regulation of Oncogenes by MicroRNAs.
JA072178 - Sequence 108 from Patent EP2298897.
JC192503 - Sequence 108 from Patent EP2338993.
JC246423 - Sequence 108 from Patent EP2338994.
JD048827 - Sequence 29851 from Patent EP1572962.
CS545000 - Sequence 109 from Patent WO2006028967.
DL262826 - Regulation of Oncogenes by MicroRNAs.
HW270305 - JP 2012105669-A/101: Regulation of Oncogenes by MicroRNAs.
JA072179 - Sequence 109 from Patent EP2298897.
JC192504 - Sequence 109 from Patent EP2338993.
JC246424 - Sequence 109 from Patent EP2338994.
JD237484 - Sequence 218508 from Patent EP1572962.
MA581940 - JP 2018138019-A/153866: Polycomb-Associated Non-Coding RNAs.
MA581942 - JP 2018138019-A/153868: Polycomb-Associated Non-Coding RNAs.
MA448945 - JP 2018138019-A/20871: Polycomb-Associated Non-Coding RNAs.
MA441168 - JP 2018138019-A/13094: Polycomb-Associated Non-Coding RNAs.
LY605668 - KR 1020180081836-A/14: RNA PREPARATIONS COMPRISING PURIFIED MODIFIED RNA FOR REPROGRAMMING CELLS.

-  Biochemical and Signaling Pathways
  BioCarta from NCI Cancer Genome Anatomy Project
h_ctcfPathway - CTCF: First Multivalent Nuclear Factor
h_mapkPathway - MAPKinase Signaling Pathway
h_pparaPathway - Mechanism of Gene Regulation by Peroxisome Proliferators via PPARa(alpha)
h_tertpathway - Overview of telomerase protein component gene hTert Transcriptional Regulation
h_cardiacegfPathway - Role of EGF Receptor Transactivation by GPCRs in Cardiac Hypertrophy
h_wntPathway - WNT Signaling Pathway
h_cdMacPathway - Cadmium induces DNA synthesis and proliferation in macrophages
h_gleevecpathway - Inhibition of Cellular Proliferation by Gleevec
h_telPathway - Telomeres, Telomerase, Cellular Aging, and Immortality
h_vipPathway - Neuropeptides VIP and PACAP inhibit the apoptosis of activated T cells
h_erkPathway - Erk1/Erk2 Mapk Signaling pathway
h_il2rbPathway - IL-2 Receptor Beta Chain in T cell Activation
h_p38mapkPathway - p38 MAPK Signaling Pathway
h_arfPathway - Tumor Suppressor Arf Inhibits Ribosomal Biogenesis

Reactome (by CSHL, EBI, and GO)

Protein P01106 (Reactome details) participates in the following event(s):

R-HSA-5687083 MYC binds MAPKAPK5 gene
R-HSA-8865265 TFAP2C homodimer binds MYC and KDM5B
R-HSA-8932400 MYC:MAX binds the CDC25A gene
R-HSA-8865280 TFAP2C homodimer binds the CDKN1A (p21) gene promoter
R-HSA-5696914 USP28 deubiquitinates CLSPN and MYC
R-HSA-9011984 KDM1A is recruited to MYC and BCL2 genes
R-HSA-9011983 Overexpressed HIST1H2AC and ESR1:ESTG bind MYC and BCL2 genes
R-HSA-9011981 EP300 is recruited to MYC and BCL2 genes
R-HSA-9011985 KDM1A demethylates H3 on MYC and BCL genes in response to estrogen
R-HSA-5687128 MAPK6/MAPK4 signaling
R-HSA-8866911 TFAP2 (AP-2) family regulates transcription of cell cycle factors
R-HSA-2173796 SMAD2/SMAD3:SMAD4 heterotrimer regulates transcription
R-HSA-2122947 NOTCH1 Intracellular Domain Regulates Transcription
R-HSA-2644606 Constitutive Signaling by NOTCH1 PEST Domain Mutants
R-HSA-2894862 Constitutive Signaling by NOTCH1 HD+PEST Domain Mutants
R-HSA-4411364 Binding of TCF/LEF:CTNNB1 to target gene promoters
R-HSA-8951430 RUNX3 regulates WNT signaling
R-HSA-9018519 Estrogen-dependent gene expression
R-HSA-69202 Cyclin E associated events during G1/S transition
R-HSA-6785807 Interleukin-4 and 13 signaling
R-HSA-5683057 MAPK family signaling cascades
R-HSA-8864260 Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors
R-HSA-2173793 Transcriptional activity of SMAD2/SMAD3:SMAD4 heterotrimer
R-HSA-1980143 Signaling by NOTCH1
R-HSA-2644602 Signaling by NOTCH1 PEST Domain Mutants in Cancer
R-HSA-2894858 Signaling by NOTCH1 HD+PEST Domain Mutants in Cancer
R-HSA-201722 Formation of the beta-catenin:TCF transactivating complex
R-HSA-8878159 Transcriptional regulation by RUNX3
R-HSA-8939211 ESR-mediated signaling
R-HSA-69206 G1/S Transition
R-HSA-5689880 Ub-specific processing proteases
R-HSA-449147 Signaling by Interleukins
R-HSA-162582 Signal Transduction
R-HSA-212436 Generic Transcription Pathway
R-HSA-170834 Signaling by TGF-beta Receptor Complex
R-HSA-157118 Signaling by NOTCH
R-HSA-2644603 Signaling by NOTCH1 in Cancer
R-HSA-201681 TCF dependent signaling in response to WNT
R-HSA-9006931 Signaling by Nuclear Receptors
R-HSA-453279 Mitotic G1-G1/S phases
R-HSA-5688426 Deubiquitination
R-HSA-1280215 Cytokine Signaling in Immune system
R-HSA-73857 RNA Polymerase II Transcription
R-HSA-9006936 Signaling by TGF-beta family members
R-HSA-5663202 Diseases of signal transduction
R-HSA-195721 Signaling by WNT
R-HSA-69278 Cell Cycle (Mitotic)
R-HSA-597592 Post-translational protein modification
R-HSA-168256 Immune System
R-HSA-74160 Gene expression (Transcription)
R-HSA-1643685 Disease
R-HSA-1640170 Cell Cycle
R-HSA-392499 Metabolism of proteins

-  Other Names for This Gene
  Alternate Gene Symbols: A0A024R9L7, A0A087WUS5, A8WFE7, BHLHE39, ENST00000621592.1, ENST00000621592.2, ENST00000621592.3, ENST00000621592.4, ENST00000621592.5, ENST00000621592.6, ENST00000621592.7, H0YBT0, MYC_HUMAN, NM_002467, P01106, P01107, Q14026, uc327tsx.1, uc327tsx.2
UCSC ID: ENST00000621592.8_13
RefSeq Accession: NM_002467.6
Protein: P01106 (aka MYC_HUMAN)

-  Gene Model Information
  Click here for a detailed description of the fields of the table above.

-  Methods, Credits, and Use Restrictions
  Click here for details on how this gene model was made and data restrictions if any.